Indication
GM1 in the Prevention of Albumin-paclitaxel Therapy Induced Peripheral Neuropathy
1 clinical trial
1 product
Clinical trial
a Multicenter, Randomized, Double-blind Phase II Trial To Evaluate Monosialate Tetrahexose-ganglioside Sodium Injection (GM1) for Prevention of Peripheral Neuropathy in Patients With Breast Cancer Induced by Albumin-bound Paclitaxel Regimen Adjuvant/Neoadjuvant TherapyStatus: Not yet recruiting, Estimated PCD: 2024-12-31